ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1019

Targeting the Bone-Driven Metabolic OA Phenotype By a Novel Dual Amylin Calcitonin Receptor Agonist, KBP-056

Ditte Reker, Sara Toftegaard Hjuler, Kim Andreassen, Morten Asser Karsdal, Kim Henriksen and Anne C. Bay-Jensen, Nordic Bioscience, Biomarkers and Research, Herlev, Denmark

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Bone, cartilage, Metabolism, osteoarthritis and treatment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Biology and Pathology of Bone and Joint: Cartilage, Synovium and Osteoarthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Osteoarthritis (OA) may be segregated into different disease phenotypes based on disease drivers; cartilage damage, joint inflammation or subchondral bone remodelling. Each phenotype may require targeted treatments. Patients with a bone-driven OA may particularly benefit from a treatment with anti-resorptive and chondro-protective properties. Salmon calcitonin (sCT), a hormone acting through CT and amylin receptors, have in multiple preclinical models been demonstrated to improve bone homeostasis and attenuate joint destruction, in part through the anti-resorptive property. In addition, sCT have recently been shown to have a positive effect on obesity and diabetes, which may benefit certain OA subjects. Several Dual Amylin Calcitonin Receptor Agonists (DACRAs) were characterized through a larger screening program; KBP-056 was found to be particular interesting for OA, by showing higher potency for the receptors than sCT. The objective of this study was to investigate the in vivo effect of KBP-056 on bone and cartilage turnover, as well as metabolic health.

Methods: Male Sprague Dawley rats (Taconic, Ry, Denmark) were given HFD for 10 weeks before they were treated with defined doses of KBP-056 (0.625, 1.25, 2.5, 5, 10 ug/Kg) or vehicle as subcutaneous injections. Blood was collected from overnight fasted rats immediately at baseline, 3 and 24 hours after first treatment.  Rats were treated for 8 weeks. Body weight was recorded weekly. Biomarkers of bone and cartilage degradation were assessed in the blood using the ELISAs CTX-I (bone resorption) and CTX-II (cartilage degradation). CTX-I and -II were reported as fold of baseline levels, as means with standard error of mean (SEM) and compared using two-way ANOVA assuming normal distribution. Significance levels; *P < 0.05, **P < 0.01, ***P < 0.001. In addition, a similar study was performed using ovariectomy (OVX)-meniscectomy (MNX) Sprague Dawley rats.

Results: Serum levels of both CTX-I and -II decrease significantly 3 hours after treatment with KBP-056, even at the lowest dose tested (P<0.05, fig. 1). Moreover, a dose-dependent response by CTX-I still remained 24 hours after treatment, suggesting increased potency. KBP-056 caused a 19% vehicle-corrected weight reduction for two highest doses at the end of the experiment. A similar weight reducing effect was observed in OVX-MNX rats.

Conclusion: The data presented here clearly indicate a protective effect of KBP-056 on both bone and cartilage in vivo, when evaluated by biochemical markers. Furthermore, KBP-056 has demonstrated positive effects on metabolic health (cause a weight decrease), and may therefore represent a possible treatment opportunity for bone-driven OA, with an unhealthy phenotype (e.g. high BMI). Many further studies are needed to match the optimal treatment opportunity with the right OA patient for a personalized health care approach for OA.  

 

 


Disclosure:

D. Reker,

Nordic Bioscience Diagnostic,

3;

S. T. Hjuler,

Nordic Bioscience Diagnostic,

3;

K. Andreassen,

Nordic Bioscience Diagnostic,

3;

M. A. Karsdal,

Nordic Bioscience Diagnostic,

3,

AbbVie Inc.,

5;

K. Henriksen,

Nordic Bioscience Biomarkers and Reasearch,

3;

A. C. Bay-Jensen,

Nordic Bioscience Holding A/S,

1,

Nordic Bioscience Diagnostic,

3.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/targeting-the-bone-driven-metabolic-oa-phenotype-by-a-novel-dual-amylin-calcitonin-receptor-agonist-kbp-056/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology